scholarly journals Prediction of Metabolic Syndrome by Low Serum Testosterone Levels in Men: Results From the Study of Health in Pomerania

Diabetes ◽  
2009 ◽  
Vol 58 (9) ◽  
pp. 2027-2031 ◽  
Author(s):  
R. Haring ◽  
H. Volzke ◽  
S. B. Felix ◽  
S. Schipf ◽  
M. Dorr ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Serum Testosterone ◽  
Testosterone Levels ◽  
Low Serum

Low serum testosterone levels are predictive of prostate cancer

2011 ◽  
Vol 31 (2) ◽  
pp. 247-252 ◽  
Author(s):  
Luigi Mearini ◽  
Alessandro Zucchi ◽  
Elisabetta Nunzi ◽  
Tommaso Villirillo ◽  
Vittorio Bini ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Serum Testosterone ◽  
Testosterone Levels ◽  
Low Serum

Testosterone Treatment Is Associated with Reduced Mortality in Men with Low Serum Testosterone Levels

2011 ◽  
pp. P1-772-P1-772
Author(s):  
Molly M Shores ◽  
Nicholas L Smith ◽  
Christopher W Forsberg ◽  
Bradley D Anawalt ◽  
Alvin M Matsumoto
Keyword(s):  
Serum Testosterone ◽  
Testosterone Treatment ◽  
Testosterone Levels ◽  
Low Serum

Serum testosterone level and overall survival in first-line abiraterone and enzalutamide for metastatic castration-resistant prostate cancer patients.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e17545-e17545
Author(s):  
Maysa Tamara Silveira Vilbert ◽  
Marcelle Goldner Cesca ◽  
Natasha Carvalho Pandolfi ◽  
Vinicius Fernando Calsavara ◽  
Bruno Cezar de Mendonça Uchôa ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Overall Survival ◽  
Testosterone Level ◽  
Serum Testosterone ◽  
Serum Testosterone Level ◽  
Castration Resistant Prostate Cancer ◽  
First Line ◽  
Testosterone Levels ◽  
Castration Resistant ◽  
Low Serum

e17545 Background: Androgen receptor-targeted agents Abiraterone and Enzalutamide (Abi/Ez) prolonged overall survival in metastatic castration resistant prostate cancer (mCRPC). Patients with very-low serum testosterone levels seem to have less benefit from these therapies as well as more aggressive prostate cancer. Methods: A retrospective observational cohort study was conducted to evaluate whether a serum testosterone measured at time of start first-line therapy with Abi/Ez is related to overall survival (OS) and time-to-treatment failure (TTF) in mCRPC patients. Kaplan-Meier survival estimates and Cox-regression models were used for time-to-event analyses. The best cut-off for testosterone was defined using Log-rank statistics (Lausen and Schumacher). X² test and Mann-Whitney U-test were applied to compare categorical and continuous variables, respectively. Logistic regression was used to assess characteristics related to serum testosterone levels. Statistical significance was fixed at 0.05. Results: From May 2012 to February 2017, 100 patients were assessed. Median follow-up was 27.8 months (range 2.23 to 68.26). Pts with a high testosterone level ( > 28.2; n = 20) achieved a significantly higher OS (median 66.0 vs 31.9 mo, testosterone > 28.2 HR: 0.206, 95% CI 0.074 to 0.571, p = 0.002) and TTF (median 30.6 vs 11.8 mo, testosterone > 28.2 HR: 0.408, 95%CI 0.219 to 0.762, p = 0.005) than pts with a low serum testosterone level ( < 28.2; n = 80), regardless of receiving therapy with either Abi (n = 69) or Ez (n = 31). Pts with a higher testosterone level were younger (median 67.7 vs 73.6 years; p = 0.026), had a higher body mass index (BMI) (28.5 vs 25.9, p = 0.023) and a lower PSA at start Abi/Ez (12 vs 26, p = 0.031) than pts with lower values. Age (OR 0.93, 95%CI 0.8 to 0.9, p = 0.021), BMI (OR 1.21, 95%CI 1.1 to 1.4, p = 0.006) and baseline PSA (OR 1.2, 95%CI 1.03 to 1.4, p = 0.020) were significantly associated with testosterone > 28.2. After 4 months of Abi/Ez treatment, PSA decrease > 50% of baseline was seen more frequently in high testosterone levels group than in low testosterone levels pts (90% vs 57.5% of pts, respectively, p = 0.007). Conclusions: Pts with high levels of testosterone ( > 28.2) achieved a better OS and TTF when treated with Abi/Ez in first-line mCRPC than those with low levels. Testosterone can be considered a prognostic and predictive biomarker in this scenario, and could be used in treatment decision for this population.

ASSOCIATION BETWEEN ENDOTHELIAL DYSFUNCTION AND LOW SERUM TESTOSTERONE LEVELS

2009 ◽  
Vol 181 (4S) ◽  
pp. 367-367
Author(s):  
Osama Mohamed ◽  
John S Colen ◽  
Larry I Lipshultz ◽  
Mohit Khera
Keyword(s):  
Endothelial Dysfunction ◽  
Serum Testosterone ◽  
Testosterone Levels ◽  
Low Serum
Sign in / Sign up

Export Citation Format

Share Document